152 related articles for article (PubMed ID: 16398403)
41. [Influence of chemiotherapeutic protocol and neuroendocrine differentiation on metastatic non-small cell lung cancer treatment results].
Tomić I; Petrović M; Plavec G; Ilić S
Vojnosanit Pregl; 2007 Sep; 64(9):591-6. PubMed ID: 17969813
[TBL] [Abstract][Full Text] [Related]
42. Evaluation of chromogranin A expression in serum and tissues of breast cancer patients.
Giovanella L; Marelli M; Ceriani L; Giardina G; Garancini S; Colombo L
Int J Biol Markers; 2001; 16(4):268-72. PubMed ID: 11820723
[TBL] [Abstract][Full Text] [Related]
43. Biological variation of neuroendocrine tumor markers chromogranin A and neuron-specific enolase.
Braga F; Ferraro S; Mozzi R; Dolci A; Panteghini M
Clin Biochem; 2013 Jan; 46(1-2):148-51. PubMed ID: 23000312
[TBL] [Abstract][Full Text] [Related]
44. Diagnostic Immunostaining and Tumor Markers Predict the Prognosis of Esophageal Neuroendocrine Cell Carcinoma Patients.
Sohda M; Saeki H; Kuwano H; Miyazaki T; Yokobori T; Sano A; Sakai M; Kakeji Y; Toh Y; Doki Y; Matsubara H
Ann Surg Oncol; 2021 Nov; 28(12):7983-7989. PubMed ID: 33843025
[TBL] [Abstract][Full Text] [Related]
45. Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience.
Linnoila RI; Piantadosi S; Ruckdeschel JC
Chest; 1994 Dec; 106(6 Suppl):367S-371S. PubMed ID: 7988266
[TBL] [Abstract][Full Text] [Related]
46. [Analysis of clinicopathological features of intestinal neuroendocrine neoplasms].
Gao W; Liu SM; Lu HZ; Liang J; Yuan YL; Liu XY
Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):450-6. PubMed ID: 22967448
[TBL] [Abstract][Full Text] [Related]
47. Neuroendocrine differentiation and nerves in human adrenal cortex and cortical lesions.
Li Q; Johansson H; Kjellman M; Grimelius L
APMIS; 1998 Aug; 106(8):807-17. PubMed ID: 9744767
[TBL] [Abstract][Full Text] [Related]
48. Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer.
Lilleby W; Paus E; Skovlund E; Fosså SD
Prostate; 2001 Feb; 46(2):126-33. PubMed ID: 11170140
[TBL] [Abstract][Full Text] [Related]
49. Prognostic value of serum tumor markers in patients with lung cancer.
Hatzakis KD; Froudarakis ME; Bouros D; Tzanakis N; Karkavitsas N; Siafakas NM
Respiration; 2002; 69(1):25-9. PubMed ID: 11844959
[TBL] [Abstract][Full Text] [Related]
50. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer.
Fan L; Wang Y; Chi C; Pan J; Xun S; Xin Z; Hu J; Zhou L; Dong B; Xue W
BJU Int; 2017 Aug; 120(2):226-232. PubMed ID: 28107595
[TBL] [Abstract][Full Text] [Related]
51. Neuroendocrine differentiation in non-small cell lung cancer and its relation to prognosis and therapy.
Howe MC; Chapman A; Kerr K; Dougal M; Anderson H; Hasleton PS
Histopathology; 2005 Feb; 46(2):195-201. PubMed ID: 15693892
[TBL] [Abstract][Full Text] [Related]
52. Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects.
Isgrò MA; Bottoni P; Scatena R
Adv Exp Med Biol; 2015; 867():125-43. PubMed ID: 26530364
[TBL] [Abstract][Full Text] [Related]
53. Canine Clitoral Carcinoma: A Clinical, Cytologic, Histopathologic, Immunohistochemical, and Ultrastructural Study.
Verin R; Cian F; Stewart J; Binanti D; MacNeill AL; Piviani M; Monti P; Baroni G; Le Calvez S; Scase TJ; Finotello R
Vet Pathol; 2018 Jul; 55(4):501-509. PubMed ID: 29444629
[TBL] [Abstract][Full Text] [Related]
54. Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology.
Molina R; Augé JM; Bosch X; Escudero JM; Viñolas N; Marrades R; Ramírez J; Carcereny E; Filella X
Tumour Biol; 2009; 30(3):121-9. PubMed ID: 19506400
[TBL] [Abstract][Full Text] [Related]
55. [Significance of serum neuron-specific enolase before treatment in predicting brain metastases and prognosis of advanced non-small cell lung cancer].
Chen Y; Peng W; Huang Y; Chen J; Su G; Jiang C; Xiao Y
Zhonghua Zhong Liu Za Zhi; 2015 Jul; 37(7):508-11. PubMed ID: 26463326
[TBL] [Abstract][Full Text] [Related]
56. Bcl2 expression and its correlation with neuroendocrine differentiation in colon carcinomas.
Atasoy P; Bozdoğan O; Oztürk S; Ensari A
Tumori; 2004; 90(2):233-8. PubMed ID: 15237588
[TBL] [Abstract][Full Text] [Related]
57. Prediction of lung cancer based on serum biomarkers by gene expression programming methods.
Yu Z; Chen XZ; Cui LH; Si HZ; Lu HJ; Liu SH
Asian Pac J Cancer Prev; 2014; 15(21):9367-73. PubMed ID: 25422226
[TBL] [Abstract][Full Text] [Related]
58. Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer.
Pujol JL; Quantin X; Jacot W; Boher JM; Grenier J; Lamy PJ
Lung Cancer; 2003 Feb; 39(2):131-8. PubMed ID: 12581564
[TBL] [Abstract][Full Text] [Related]
59. [Expression of CD56, as a potential diagnostic marker, in small cell carcinoma].
Yun JP; Xiang J; Hou JH; Tian QH; Fu J
Ai Zheng; 2005 Sep; 24(9):1140-3. PubMed ID: 16159442
[TBL] [Abstract][Full Text] [Related]
60. [Establishment of cut-off value of serum pro-gastrin-releasing peptide for diagnosis of small cell lung cancer and evaluation on the clinical diagnosis efficiency].
Shen D; Han BB; Chen F; Wei BJ; Cui CJ; Wang GJ; Cui W
Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2657-2662. PubMed ID: 28910952
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]